Kraljević Marko, Delko Tarik, Köstler Thomas, Osto Elena, Lutz Thomas, Thommen Sarah, Droeser Raoul A, Rothwell Lincoln, Oertli Daniel, Zingg Urs
Department of General Surgery, University Hospital Basel, 4031, Basel, Switzerland.
Department of General Surgery, Limmattal Hospital, 8952, Zurich-Schlieren, Switzerland.
Trials. 2017 May 22;18(1):226. doi: 10.1186/s13063-017-1957-9.
Laparoscopic Roux-en-Y gastric bypass (LRYGB) is considered the gold standard in bariatric surgery, achieving durable long-term weight loss with improvement of obesity-related comorbidities. Lately, the laparoscopic mini gastric bypass (LMGB) has gained worldwide popularity with similar results to LRYGB in terms of weight loss and comorbidity resolution. However, there is a lack of randomized controlled trials (RCT) comparing LMGB and LRYGB. This article describes the design and protocol of a randomized controlled trial comparing the outcomes of these two bariatric procedures.
METHODS/DESIGN: The trial is designed as a single center, randomized, patient and observer blinded trial. The relevant ethics committee has approved the trial protocol. To demonstrate that LMGB is not inferior to LRYGB in terms of excess weight loss (EWL) the study is conducted as a non-inferiority trial with the sample-size calculations performed accordingly. EWL 12 months after surgery is the primary endpoint, whereas 3-year EWL, morbidity, mortality, remission of obesity related comorbidities, quality of life (QOL) and hormonal and lipid profile changes are secondary endpoints. Eighty patients, 18 years or older and with a body mass index (BMI) between 35 and 50 kg/m who meet the Swiss guidelines for the surgical treatment of morbid obesity will be randomized. The endpoints and baseline measurements will be assessed pre-surgery, peri-surgery and post-surgery (fixed follow up measurements are at discharge and at the time points 6 weeks and 12 and 36 months postoperatively).
With its 3-year follow up time, this RCT will provide important data on the impact of LMGB and LRYGB on EWL, remission of comorbidities, QOL and hormonal and lipid profile changes.
ClinicalTrials.gov, NCT02601092 . Registered on 28 September 2015.
腹腔镜Roux-en-Y胃旁路术(LRYGB)被认为是减肥手术的金标准,可实现持久的长期体重减轻,并改善肥胖相关的合并症。最近,腹腔镜迷你胃旁路术(LMGB)在全球范围内受到欢迎,在体重减轻和合并症解决方面与LRYGB有相似的结果。然而,缺乏比较LMGB和LRYGB的随机对照试验(RCT)。本文描述了一项比较这两种减肥手术结果的随机对照试验的设计和方案。
方法/设计:该试验设计为单中心、随机、患者和观察者双盲试验。相关伦理委员会已批准试验方案。为了证明LMGB在超重减轻(EWL)方面不劣于LRYGB,该研究作为一项非劣效性试验进行,并相应地进行了样本量计算。术后12个月的EWL是主要终点,而3年EWL、发病率、死亡率、肥胖相关合并症的缓解、生活质量(QOL)以及激素和血脂谱变化是次要终点。将对符合瑞士病态肥胖手术治疗指南的80名18岁及以上、体重指数(BMI)在35至50 kg/m之间的患者进行随机分组。终点和基线测量将在术前、围手术期和术后进行评估(固定的随访测量时间为出院时以及术后6周、12个月和36个月的时间点)。
通过其3年的随访时间,这项RCT将提供关于LMGB和LRYGB对EWL、合并症缓解、QOL以及激素和血脂谱变化影响的重要数据。
ClinicalTrials.gov,NCT02601092。于2015年9月28日注册。